Nigeria Health
Mojisola Adeyeye
Director General, National Agency for Food and Drug Administration and Control (NAFDAC)
NAFDAC developed its own quality management and auditing systems in cooperation with the World Health Organisation (WHO) that met international benchmarks, and the agency has been working with the WHO to expand our capacity to handle future pandemics.
Health Care in Nigeria
Report Article
Health Care Overview
Although Nigeria has made tangible progress on a number of health and wellness indicators in recent years, the socio-economic and medical impacts of the Covid-19 pandemic took their toll, and the country continues to grapple with challenges.
Report Article
Regulation & Oversight
The FMH is the main government body responsible for providing health services for all Nigerian citizens, with a mandate to implement policies that strengthen the national health system in order to deliver affordable services in partnership with multiple stakeholders.
Report Article
Sector Strategy
In December 2020 Dr Osagie Ehanire, the minister of health, held a press briefing to present the country’s health roadmap for 2021.
Report Article
Key Indicators
Nigeria has recorded notable improvements on several major health and wellness indicators over recent decades, with the World Bank reporting that life expectancy at birth increased by 19% from 46 years in 1998 to 54.7 years in 2019.
Report Article
Private Initiatives
Nigeria finances its health care delivery through a combination of public and private sector initiatives.
Report Article
Covid-19 Vaccination Campaign
In the second year of the pandemic, policy focus in Nigeria shifted to the rollout of Covid-19 vaccines and efforts to prevent new waves of infection.
Health Care Overview
Regulation & Oversight
Sector Strategy
Key Indicators
Private Initiatives
Covid-19 Vaccination Campaign
Kunle Oyelana
Managing Director, GSK Nigeria
Nigeria presents substantial investment and growth opportunities for the pharmaceutical industry as a result of strong local demand. As the country with both the largest economy and consumer market on the continent, Nigeria is one of the most important markets for the pharmaceutical industry in the world.
Pharmaceutical Industry
Report Article
Pharmaceutical Industry Overview
Nigeria’s pharmaceutical industry was worth an estimated $1.4bn in 2016. It has the potential to reach $4bn by 2026, representing a compound annual growth rate (CAGR) of 11%, according to a 2017 report by consultancy McKinsey.
Report Article
Local Production
Nigeria has around 115 pharmaceutical firms that produce analgesics, antimalarials, antibiotics, anti-retroviral drugs and vitamins for use in the domestic market, as well as for neighbouring countries.
Report Article
Research & Development
In 2002 Nigeria was one of 10 African countries to endorse a target of allocating 1% of GDP to research and development (R&D); however, the country has fallen short of this goal in the intervening years, with the government pledging to spend 0.5% of GDP on R&D in 2021.
Report Article
Combatting Counterfeits
Counterfeit medicine is a significant issue in the region, with the World Health Organisation (WHO) estimating that Africa accounted for as much of 42% of the world’s fake drugs.
Pharmaceutical Industry Overview
Local Production
Research & Development
Combatting Counterfeits
Case Study
Bayer is an internationally operating German life science company with over 150 years of experience in health care and agriculture. In 2015 Bayer expanded its presence in West and Central Africa. Bayer Nigeria aims to improve the quality of life for the country’s growing population by preventing, alleviating and treating diseases, as well as by providing a reliable supply of high-quality food, feed and plant-based raw materials.
With more than 115 registered pharmaceutical manufacturers providing a variety of products to health care professionals, the pharmaceutical industry in Nigeria holds significant growth potential and could be valued at $4bn by 2030, which will underpin broader economic growth. However, the country remains highly dependent on imports to supply its pharmaceutical market.
As governments and businesses continue to take note of this high-potential industry, they also face significant challenges, which include facilitating access to pharmacies in remote areas, strict monitoring and control of distributors of patented drugs, and improving the performance of the logistics chain on a national scale.
The ongoing efforts of the authorities and the industry’s biggest players are mainly focused on facilitating access to quality pharmaceuticals for Nigerians. This is expected to stimulate the growth of the sector, and positively impact the overall health and well-being of the country’s population.
Opportunities & Developments
Report Article
Investment Potential
Against the backdrop of limited public spending and a growing burden of care for an expanding population, there are substantial opportunities for private investment in Nigeria’s health sector.
Report Article
Government Incentives
While the underlying fundamentals of the health care sector and Nigeria’s demographics already make a strong case for investment, government incentives are helping to increase the market’s attractiveness further.
Report Article
Devices & Equipment
According to Fitch Solutions, the Nigerian medical device market is projected to grow at a compound annual growth rate (CAGR) of 15% between 2018 and 2023 to reach N82.7bn.
Report Article
Medical Technology
Technology is transforming health provision in emerging markets — not only in terms of extending care to underserved areas, but also by allowing hospitals to digitise patients records to provide diagnosis and care remotely.